HOME >> MEDICINE >> NEWS
Cancer drug can extend survival in patients with deadly brain tumors

DURHAM, N.C. -- Avastin, a relatively new type of drug that shrinks cancerous tumors by cutting off their blood supply, can slow the growth of the most common and deadly form of brain cancer, a pilot study conducted at Duke University Medical Center has found.

The study marks the first time that Avastin has been tested against brain tumors, the researchers said. The drug, whose chemical name is bevacizumab, currently is used to treat lung and colorectal cancers.

The researchers tested the effectiveness of Avastin in conjunction with a standard chemotherapy agent in patients with recurrent cancerous brain tumors called gliomas. They found that the two drugs together halted tumor growth up to twice as long as comparative therapies. Though gliomas remain incurable in nearly all cases, the combined drug therapy may buy precious time and preserve physical and mental function longer for patients facing this grim diagnosis, the researchers said.

"These results are exciting because of the possible implications for a patient population that currently has the poorest possible prognosis going into treatment, those with malignant brain tumors that have recurred after initial treatment," said James Vredenburgh, M.D., a brain cancer specialist at Dukes Preston Robert Tisch Brain Tumor Center and lead researcher on the study.

The findings will appear in the Feb. 20, 2007, issue of the journal Clinical Cancer Research. The study was funded by the National Institutes of Health, the Preston Robert Tisch Brain Tumor Research Fund, the Bryan Cless Research Fund and Genentech, the maker of Avastin.

Duke currently is participating in a large, multi-institutional study of Avastin to corroborate the results of this initial study, Vredenburgh said.

Kate Carr, president and chief executive officer of Accelerate Brain Cancer Cure, a not-for-profit organization that supports research to hasten a cure for brain cancer, said, "The re
'"/>

Contact: Lauren Shaftel
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
20-Feb-2007


Page: 1 2 3

Related medicine news :

1. American Cancer Society to hold third annual Virtual Relay For Life in Second Life
2. Cancer research summaries
3. Cancer on the agenda of the Portuguese EU Council Presidency
4. Tony Hunter receives Robert. J. and Claire Pasarow Award for Cancer Research
5. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
6. OHSU Cancer Institute, VA researchers find way to identify which men need a second biopsy
7. OHSU Cancer Institute researcher identifies protein marker for prostate cancer survival
8. Ireland Cancer Center researcher lays out benefits of aspirin to prevent colon cancer
9. Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma
10. Margaret Foti receives AACR Award for Leadership and Extraordinary Achievements in Cancer Research
11. Cancer-fighting foods, supplements explored in day-long symposium, March 25

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cancer drug can extend survival patients with deadly brain tumors

(Date:7/3/2015)... ... July 03, 2015 , ... ... July 2nd creating a buzz of media attention. In an effort to spread ... HonestyFirstReviews.com's Tiffany Hendricks. , "These days many people are feeling overwhelmed by stress ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... speaker lineup for its 2015 Annual Conference , the premiere continuing ... at the Renaissance Orlando at SeaWorld in Orlando, Florida. Speakers include the ...
(Date:7/3/2015)... ... 2015 , ... Renowned rhinoplasty surgeon and Symposium Chairman, Dr. ... Symposium . To be held from March 4th - 6th, the 2016 (a previous ... Galleria Dallas. , Designed to take participants from the basic training and fundamentals of ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... healthcare providers, has been retained to lead a national chief nursing officer ... top-ranked executive search firms in the healthcare industry, B. E. Smith has recently ...
(Date:7/3/2015)... ... 03, 2015 , ... Smoothies are all the rage right now and all ... quality ingredients. Aurora Natural is proud to introduce a new line of all natural ... antioxidants, vitamins and minerals! , Aurora is offering a variety of blends and stand-alone ...
Breaking Medicine News(10 mins):Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2
(Date:7/2/2015)... , July 2, 2015 Pharma Major ... in ZAO "Biocom" in Russia subject ... the Russian pharmaceutical market which recorded RUB 765 billion in ... markets in the world in 2014 (IMS Health). For over ... expected to continue with this trend, projecting Russia ...
(Date:7/2/2015)... DURHAM, N.C. , July 2, 2015 /PRNewswire/ ... acquisition of assets related to the ion channel biology ... had previously been obtained as part of Pfizer,s 2011 ... of Pfizer,s rights to the "Icagen" name and trademark. ... provide comprehensive services for ion channel and transporter drug ...
(Date:7/2/2015)... 2015 Research ... addition of the "2015 New Frontiers ... Emerging Technologies, Competitive Landscape" report to ... in Clinical Chemistry and Immunodiagnostics: Global Challenges, ... seven-country strategic analysis of major business opportunities ...
Breaking Medicine Technology:Lupin Acquires Biocom in Russia 2Lupin Acquires Biocom in Russia 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2
Cached News: